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bone. This supposition is supported by these data as concentrations of
uCTXII were highly correlated to the severity of OA as measured by osteo-
phyte formation, particularly of the medial compartment. The signiﬁcant
association of concentrations of collagenous urinary markers, ALPHA CTX
and CTXII, to knee bone turnover by bone scintigraphy suggests that these
markers may be useful non-invasive surrogates for active bone turnover in
knee osteoarthritis.
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Purpose: Osteoarthritis (OA) is the most common rheumatic pathology,
characterized mainly by cartilage degradation. Despite its high preva-
lence, the diagnosis methods currently available are limited and lacked
of sensitivity. Therefore, there is a considerable interest pointed in the
characterization of new speciﬁc OA biomarkers in biological ﬂuids. In
this work we aimed to set up a proteomic method for the large-scale
identiﬁcation and quantisation of proteins in serum from OA patients and
their comparison with healthy donors.
Methods: Serum samples were obtained from OA patients at different
stages of the disease (50 samples from grade II and 50 from grade IV),
and 50 control donors. To reduce interindividual variability, samples were
grouped in pools made from 10 patients. To reduce the dynamic range of
protein concentrations and be able to identify minority proteins, the top
twenty most abundant proteins in crude serum ﬂuids were removed by
aﬃnity chromatography using the immunodepletion column ProteoPrep®
20 (Sigma Aldrich). Proteins from each pool were quantiﬁed, digested with
trypsin and differentially labelled with isobaric tags using iTRAQ method-
ology (ABSCIEX). Then, peptides from the three conditions were mixed,
separated and analyzed by two dimensional LC coupled to MALDI-TOF/TOF
mass spectrometry. Identiﬁcation and relative quantiﬁcation of the proteins
were performed using ProteinPilot 2.0 software (ABSCIEX). Only proteins
identiﬁed with at least 95% conﬁdence were reported. PSPEP program was
used independently to calculate False Discovery Rates.
Results: The immunodepletion and subsequent proteomic analysis of the
samples led to the identiﬁcation of around 160 different proteins in the
serum pools, with at least one peptide and a conﬁdence higher than 99.9%.
Measurement of the different iTRAQ tags intensities allowed the relative
quantiﬁcation of each protein under the three conditions of the study
(control, OA grade II and OA grade IV). At this point, we have already
analyzed results from 60 samples. Data were normalized and we considered
signiﬁcant those changes with a ratio OA:N >1.2 or <0.8 and a p-value
below 0.05.
With these considerations, 29 proteins were found to be modiﬁed in the
serum of OA patients (17 increased and 12 decreased) when compared to
Table 1. Serum Proteins altered in OA patients when compared to healthy donors
Early OA (Grade II) Late OA (Grade IV) OA (Both stages)
Increased
Apolipoprotein E Complement C4-B Alpha-1B-glycoprotein
Beta-2-microglobulin Heparin cofactor 2 Alpha-2-HS-glycoprotein
Plasma protease C1 Histidine-rich glycoprotein Apolipoprotein B-100
inhibitor Thyroxine-binding globulin CD5 antigen-like
Vitamin K-dependent prot. S Complement C3
Ig lambda chain C
Ig mu chain C
Mannose-binding protein
CN-acetylmuramoyl-L-alanine
amidase
Decreased
Apolipoprotein A-IV Alpha-2-macroglobulin Apolipoprotein A-I
Complement component Complement component C7 Attractin
C8 beta chain Plasma kallikrein Fibronectin
Glutathione peroxidase Plasma protease C1 inhibitor
Serum albumin
Zinc-alpha-2-glycoprotein
healthy donors (see Table 1). From these, 12 were altered independently
of the degree of the disease, 6 were modiﬁed only in early stages (grade
II), and 11 exclusively in advanced OA (grade IV). The reported altered
proteins, which are now putative OA biomarker candidates, are involved in
a wide range of biological functions, such as immune response, inﬂamma-
tion processes, lipid metabolism, oxidative stress defence, transport or cell
adhesion.
Conclusions: A number of novel putative OA serum protein biomarkers
have been described. Validation of these results on a higher number of
samples will be necessary for the design of a ﬁnal panel, which will
undoubtedly be useful for OA diagnosis and progression studies.
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Purpose: In kOA disease progression and chronic inﬂammation is pro-
moted by combinations of principle components of angiogenesis, the
kallikrein-kinin and rennin-angiotensin systems, which play essential roles
in the maintenance of vascular immune homeostasis.The humoral immune
response represents a form of biological ampliﬁcation of signals that are
otherwise weak due to very low concentrations of self-antigen, especially
in the early stages of kOA. To investigate the speciﬁc presence of NA
(IgM, IgG, IgA) to EM (BK, ANII, VEGF, bFGF) in the peripheral blood sera
of patients with kOA and healthy individuals: focusing on novel immune
disease-associated biomarkers of angiogenesis.
Methods: In order to quantify NA to EM in the sera, were designed,
synthesized and then used to develop an ELISA, in which antigens coupled
to matrix was coated on microtiters plates. Serum samples were incubated
in the plates, after which bound Ig anti-EM was detected with mouse
anti-human Ig-HRP. Levels NA-EM in a cohort of controls differed by more
than 100-fold, whereas the ﬂuctuation of EM-NA levels in individuals over
time was small (coeﬃcient of variation 8%). Following this procedure, we
examined variations in the levels of NA recognized a panel of self-antigens
in the sera from healthy individuals and kOA patients. Blood samples were
obtained from a cohort of 250 patients with symptomatic kOA (age range
45-79) fulﬁlling the American College of Rheumatology criteria for OA of
the knee joint and 250 age- and sex- matched healthy individuals. All
kOA patients had involvement of the knee joint with typical radiographic
changes graded Kellgren&Lawrence classiﬁcation. Pain was scored on a
visual analogue scale (VAS) immediately after walking 50 m. All kOA
patients are with persistent pain longer than 6 months. Parameters for
function were performed by Lequesne’s functional indexes.
Results: Different classes of NA (IgM, IgG, IgA) to EM (BK, ANII, VEGF, bFGF)
were detected with our ELISA protocol in the sera of kOA patients as well
as in the sera of healthy individuals. At time of inclusion kOA patients
(100%) had signiﬁcantly higher serum BK-IgG levels relative to normal
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sera (m±SD: 789±211 vs 501±98 OD ×1000; p<0.0001). At the same
time kOA patients had signiﬁcantly higher serum EM-IgG levels: 71% AII
(m±SD: 409±111 vs 274±84; p<0.0005), 59% VEGF (m±SD: 669±241 vs
471±189; p<0.0003), 35% bFGF (m±SD: 689±245 vs 455±115; p<0.009).
Serum BK-IgG overexpression in kOA patients were positively associated
with destructive changes (K&L>4; r=0.75; p<0.005). kOA patients in whom
K&L scores progress rapidly tend to have higher serum BK-IgG levels at all
time point. Elevated serum BK-IgG level was signiﬁcantly correlated with
enhanced pain (r=0.85; p<0.0001) and loss of functions (r=0.69; p<0.0003)
in kOA patients. At the same time kOA patients had signiﬁcantly lower
serum EM-IgM levels relative to normal sera: 66% AII (m±SD: 289±99 vs
455±101; p<0.0001), 79% VEGF (m±SD: 366±181 vs 559±198; p<0.005),
61% bFGF (m±SD: 521±222 vs 705±239; p<0.007). No signiﬁcant differ-
ence in binding of serum EM-IgA levels in kOA patients in comparison with
that in control. No correlations were found to conventional parameters for
pain and function with expression of EM-IgA, EM-IgM.
Conclusions: We showed that our ELISA was able to demonstrate immune
responses to each of the 4 type speciﬁc self-antigens in kOA patients. EM
represent a group of novel selfantigens which are targeted by NA from kOA
patients. Serum NA proﬁling is a promising approach for early detection
and diagnosis of kOA.This results show a speciﬁc dysbalance of Ig content
in kOA patients. Circulating BK-IgG in the sera has been proposed as a
sensitive and speciﬁc marker of diagnosing kOA at early stages of the
disease. Our results have potential applications for controlling unwanted
angiogenesis, inﬂammation, infection, pain and future response to therapy
in kOA patients.
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Purpose: Extracellular release of High Mobility Group Box 1 (HMGB1) may
exert pro-inﬂammatory activity in rheumatoid arthritis. However, the role
of HMGB1 during the progression of synovitis in osteoarthritis (OA) re-
mains unclear. We have recently demonstrated that IL-1β induces HMGB1
secretion by OA synoviocytes, suggesting the contribution of HMGB1 to
the pro-inﬂammatory effects elicited by IL-1β. In this study, we have
evaluated the effects of HMGB1 in OA synovitis and the signaling pathways
involved.
Methods: Synovial tissue samples were obtained from 15 OA patients
undergoing total knee joint replacement and 3 normal donors. HMGB1
expression was determined in both normal and OA human synovium by
immunohistochemistry and confocal microscopic procedures. OA synovio-
cytes were treated with human recombinant HMGB1 (15-25 ng/ml) in
presence or absence of IL-1 β (10 ng/ml). Gene expression was analyzed
by quantitative PCR and protein expression by Western Blot and ELISA.
MMP activity was determined by ﬂuorometric procedures and activation of
NF-κB by magnetic transfection of the reporter construct NF-κB-luc.
Results: Despite HMGB1 distribution in both normal and OA synovium
was similar (lining, sublining and vascular wall cells), the number of
HMGB1 positive cells was higher in OA, though it was also present in
inﬁltrated cells. Regarding to HMGB1 intracellular localization, we observed
that HMGB1 was mostly found in the nucleus of normal synovium cells,
whereas in OA the localization was markedly cytoplasmic. Treatment of
synoviocytes with 15 or 25 ng/ml of HMGB1 did not modify the production
of IL-6, IL-8, CCL2, CCL20 and matrix metalloproteinases (MMP)-1, 3 and
13). However, the concomitant treatment of HMGB1 with IL-1β signiﬁ-
cantly enhanced, in a dose dependent manner, both mRNA and protein
expression of these mediators, as well as MMP-activity. In addition, HMGB1
potentiated the phosphorylation of Akt, ERK 1/2 and p38 induced by IL-1β
as well as NF-κB activation.
Conclusions: Synovial HMGB1 expression is higher in OA, with a marked
cytoplasmic localization. HMGB1 can act in synergy with IL-1β, with the
consequent increase in the production of several pro-inﬂammatory and
degenerative mediators, thus contributing to synovitis progression during
OA.
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Purpose: Knee osteoarthritis (OA) is a major cause of pain and functional
disability among older people. People with knee OA tend to modify their
walking pattern to reduce pain and joint load. In addition, patients with OA
are characterised by increased inﬂammation and sensitised nerves, result-
ing in increased pain. It is unclear however if the increase in inﬂammatory
markers is related to gait characteristics, particularly knee function during
walking. The aim of this study was to examine the association between
inﬂammatory markers and pain, gait and functional parameters in people
with severe knee OA.
Methods: Nineteen patients (mean ± SEM, age 69.9±1.5 year and BMI
=29.9±0.9 kg·m-2) with severe knee OA scheduled for knee replacement
surgery participated in the study. Knee sagittal motion and moments
during walking were measured using three dimensional motion analysis
system (Vicon). The physical function, pain and stiffness were assessed
using the Western Ontario and McMaster University Osteoarthritis In-
dex. The pain level during walking and the physical activity were also
recorded using Visual analog scale (VAS 0-100mm) and The Incidental
and Planned Activity Questionnaire respectively. Muscle samples from the
vastus lateralis were taken from patients with knee OA during their knee
replacement surgery. Real-time PCR (RT-PCR) was performed to measure
the mRNA abundance of the pro-inﬂammatory cytokines; MCP-1, TNF-α,
IL-1β. The association between peak knee ﬂexion and extension motion
and moments during the stance phase of walking, pain, function and
physical activity was assessed using Pearson correlation coeﬃcient. Seven-
teen age-matched asymptomatic (MA) older people (age= 66.7±1.8 year,
BMI=29.8±1.2 kg·m-2) were used to compare gene analysis data.
Results: OA patients had signiﬁcantly greater mRNA levels of the pro-
inﬂammatory cytokines MCP-1 and TNF-α compared to MA individuals.
OA also tended to have higher levels of IL-1β compared to MA individ-
uals. Increases in pain were correlated with increases in atrogin-1 and
MCP1 (r=0.46, p=0.03; r=0.43, p=0.04, respectively). Increases in planned
physical activity was correlated with MCP-1 (r=0.46, p=0.03) and IL-1β
(r=0.43, p=0.04). TNF-α and IL-1β were signiﬁcantly correlated with peak
knee extension (r=0.54, p=0.01, r=-0.60, p≤0.001, respectively) and ﬂexion
moments (r= -0.56, p≤0.001; r=-0.49, p=0.02 respectively). Increase in IL-1β
mRNA expression was also correlated with reduced knee ﬂexion motion
during stance (r=-0.41, p=0.040. Moreover, MCP-1 was correlated with peak
knee extension moment (r=-0.50, p=0.02).
Conclusions: There is an association between increased inﬂammatory
markers and increase in pain and physical activity. Further, the results
indicate that lower knee ﬂexion moment and larger knee extension mo-
ments were correlated with increase in the inﬂammatory markers. This
gait pattern suggests that people with knee OA tend to reduce the load
over the knee joint by reducing their knee ﬂexion motion in an attempt
to minimise quadriceps use. While a causal relationship has not been
established, the unloading pattern may be a compensatory strategy related
to the presence of inﬂammatory markers. Investigation of the muscle
breakdown biomarkers is needed to better understand their role in muscle
function during walking in people with knee OA.
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Purpose: Anatomic features have been used to distinguish between trau-
